Reach Us +44-1235-425476
Alteration in Transcriptional State, as a First Step in Cancer Development | OMICS International
ISSN : 2153-2435
Pharmaceutica Analytica Acta

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Alteration in Transcriptional State, as a First Step in Cancer Development

Uchiumi F1,2*, Larsen S2 and Tanuma S2,3

1Department of Gene Regulation, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda-shi, Chiba-ken, Japan

2Research Center for RNA Science, RIST, Tokyo University of Science, Noda-shi, Chiba-ken, Japan

3Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda-shi, Chiba-ken, Japan

*Corresponding Author:
Fumiaki Uchiumi
Department of Gene Regulation
Faculty of Pharmaceutical Sciences
Tokyo University of Science
Tokyo University of Science
2641 Yamazaki, Noda-shi, Chiba-ken 278-8510, Japan
Tel: +81-4-7121-3616
Fax: +81-4-7121-3608
E-mail: [email protected]

Received date: November 04, 2014; Accepted date: November 05, 2014; Published date: December 10, 2014

Citation: Uchiumi F, Larsen S and Tanuma S (2014) Alteration in Transcriptional State, as a First Step in Cancer Development. Pharm Anal Acta 5:e166. doi:10.4172/2153-2435.1000e166

Copyright: © 2014 Uchiumi F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta



The risk of cancer, which increases in accordance with aging, has been mainly explained by the oxidative stresses that cause DNA damage. In fact, recent DNA sequencing studies of genomes from cancer patients revealed a variety of mutations on specific genes, suggesting that accumulation of DNA damage is the main cause for development of cancer. Therefore, great effort has been undertaken to analyze DNA mutations. On the other hand, especially for clinical diagnosis, abnormalities in metabolism, including up-regulation of glycolysis or “Warburg effect”, are known to be characteristics of cancer. Taken together, cancer could be referred to as both “genetic disease” and a “metabolic disease”. We have confirmed that numbers of DNA-repair- and mitochondrial function-associated gene promoters commonly contain a duplicated GGAA-motif, which is a target for multiple transcription factors. In this article, we will tentatively draw a hypothetical mechanism behind the generation of cancerous cells, in which alterations in transcriptional state have occurred primarily with repeated divisions or aging of normal cells. Thus, cancer could be regarded as a “transcriptional disease”. We hope this concept contribute for innovation of a new cancer therapeutics targeting transcription.


Cancer; DNA repair; Mitochondria; Metabolism; Senescence


It has long been argued how and why cancers are generated. In general, it is believed that cancer is a genetic disease that is resulted from mutations on driver genes, including PIK3CA, IDH1 and RB1 [1]. Moreover, next-generation sequencing enabled diagnosis of cancer and diseases that are thought to be occurred from genomic alterations [2]. Another aspect of cancer is that it is a metabolic disease [3]. It is widely known that cancer consumes more glucose to produce ATP by glycolysis or fermentation. The metabolic state of tumor cells has been referred to as the “Warburg effect” [4]. Importantly, TCA-cycle enzymes, FH (Fumarate hydratase) and SDH (Succinate Dehydrogenase) have been suggested as tumor suppressors [5]. Deficiency in oxidative phosphorylation (OxPHOS), which is dependent on an adequate supply of NADH and FADH2 from TCA cycle, has been suggested to play a causative role in cancer development [6,7]. We have confirmed that a cis-element, namely duplicated GGAA motif, is present near transcription start sites of the CS, ACO2, IDH1, IDH3A, IDH3B, SUCLG1, SDHAF2, SDHB, SDHD, FH, and ACLY genes, which encode enzymes in the TCA-cycle [8]. Moreover, the motif is contained in the bidirectional promoter regions of the genes encoding components of the OxPHOS complex, such as NDUFA1, NDUFA2, NDUFB3, NDUFB9, NDUFC1, NDUFS1, and NDUFS3 [8].

It is well established that epigenetic and/or transcriptional change play a role to determine chromatin states in tumor cells [9]. Recent genomic studies indicated alterations in gene expression in many human diseases [10,11]. Whole transcriptome analysis indicating cis - quantitative trait loci (QTLs) has been reported as of value for revealing gene expression and transcription state in cells from patients of specific disease [12]. Cancer incidence in humans increase exponentially with age, suggesting that aging is the strongest demographic risk factor for most human malignancies [13,14]. These events could be explained by reactive oxygen species (ROS) generation and accumulation of DNA damage on chromosomes or increased genomic stability, including telomere shortening [14]. Moreover, hypoxia, which attenuates response to DNA damage, increase mutation rate and chromosomal instability, may play a part in linking cancer with aging [15,16]. Importantly, aging is accompanied with epigenetic change and alteration of gene expression profile [17,18]. Numbers of GGAA motif-binding transcription factors (TFs), which act as positive and negative transcriptional regulators, may drive mitochondrial- and DNA repair-factor encoding genes simultaneously. However, repeated cell division and extracellular signals will gradually disturb the profile of TFs that bind to the GGAA (TTCC) motifs, and finally lead to disruptions in mitochondrial functions and DNA-repair systems. At this stage, cells will exhibit abnormalities in metabolism carrying mutations on DNAs. These features could be referred to as characteristics of cancer and malignant tumors. Moreover, DNA damage will activate poly(ADP-ribosyl)ation resulting in over consumption of NAD+ molecules that are required for synthesis of poly (ADP-ribose). The reduction in NAD+/NADH ratio will disturb the progression of the TCA cycle until it does not function for sufficient ATP production. In this way, cells can no longer depend on the normal respiration system, but must up-regulate glycolysis and fermentation (Figure 1).


Figure 1: Dysfunction of tricarboxylic acid (TCA) cycle, which could be caused by attenuation of GGAA-dependent transcription. Duplicated GGAA-motifs are contained in the 5’-upstream regions of the ACO2, GLUD2, IDH1, IDH3A, IDH3B, MDH2, ME2, SUCLG1, SDHAF2/SDHB/SDHD, FH, ACLY, CS, and PDHX genes. Various cellular stresses, including chemicals, X-ray and UV irradiation, virus infection, and aging, may alter the transcriptional state leading to disruption of the mitochondrial function- and DNA repair-associated gene expression. Damage on DNAs activate PARP enzyme, which consumes NAD+ molecule to synthesize poly(ADPribose), may further lead to dysfunction of the TCA-cycle. Thus cells must depend on glycolysis to synthesize ATP. The consequence could be referred to as the “Warburg effect”. This hypothesis implies that pre-cancerous state could be prevented if NAD+/NADH ratio were ameliorated.

Thus it might be too late to treat cancer after identification of mutations on driver genes, because they have already abnormalities in DNA repair and mitochondria, which frequently cause chemo-resistance. Moreover, most of the anti-cancer drugs have been developed under the concept to kill cancerous cells, but sometimes they have heavy side effects on patients. A novel concept is required to treat pre-malignant cells to be converted into benign state.

It remains unclear how the GGAA motif has been duplicated and incorporated into regulatory regions of various genes encoding DNA repair- and mitochondrial-factors. However, the duplication of TF binding site might have been advantageous for organisms in the course of evolution.

The crystal structure of mouse Elf3 with type II TGF-ß receptor promoter was reported [19], representing an association model of the ets motif binding protein with the duplicated GGAA motifs. The sequence is recognized by at least twenty seven ETS family proteins and other TFs, including GABP, NF-κB/c-Rel, and STAT proteins. Therefore, transcriptional efficiency could be fine-tuned with the distance between GGAA (TTCC) sequences, variation of the flanking sequences and the combination of the binding factors.

Here we propose a mechanism in which alterations in the transcriptional state of cells leads to insufficient mitochondrial function and DNA repair system. Given that introduction of OSKM transcription factors reprogram cells to gain pluripotent ability [20], enforced expression of specific TFs may improve metabolism in cancerous cells. In order to access this possibility, elucidation of how human genes, especially those encoding mitochondrial function- and DNA repair-associated factors, are regulated by GGAA motif-dependent transcription system. If the mechanism were revealed, novel gene therapy, such as introduction of specific TFs, could be developed to make pre-cancerous cells free from aberrant TCA cycle/respiration with unhealthy ATP-synthesis. In other words, this therapy will up-regulate DNA repair system and mitochondrial functions by modulating profile of TFs. We believe that the concept is valuable, though uncultivated as of yet, to find next generation cancer drugs with much lower side effects.


This work was supported in part by JSPS KAKENHI Grant Number 24510270 and a Research Fellowship from the Research Center for RNA Science, RIST, Tokyo University of Science.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12081
  • [From(publication date):
    December-2014 - Dec 13, 2018]
  • Breakdown by view type
  • HTML page views : 8309
  • PDF downloads : 3772

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry


[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version